Skip to main content
DYN
NASDAQ Life Sciences

Atlas Venture Funds File Intent to Sell $3.36M in Dyne Therapeutics Stock Amid Ongoing Distribution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$20.94
Mkt Cap
$3.462B
52W Low
$8.06
52W High
$25
52W Position info
160% above low
Off High info
16% below high
Rel. Volume info
3.1× avg
Market data snapshot near publication time

DYN has more than doubled off its 52-week low of $8.06 on elevated volume (3.1× avg).

Summary

A major institutional shareholder, Atlas Venture Fund XI, LP, intends to sell an additional $3.36 million of Dyne Therapeutics stock, continuing a trend of significant distribution by the fund and other insiders.


Key Events · Ownership and Investor Activity · DYN

  • Intent to Sell Additional Shares

    Atlas Venture Fund XI, LP, a shareholder, filed a Form 144 to sell 162,954 shares of common stock, valued at approximately $3.36 million.

  • Ongoing Institutional Distribution

    This proposed sale follows over $18.9 million in sales by Atlas Venture Fund XI, LP in the past three months, indicating a sustained reduction in its stake.

  • Contributes to Broader Insider Selling

    The sales by Atlas Venture are part of a larger trend of insider distribution at Dyne Therapeutics, with net insider sales exceeding $51 million over the last 90 days.


Analysis · DYN · Life Sciences

Atlas Venture Fund XI, LP, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $3.36 million worth of Dyne Therapeutics common stock. This proposed sale is part of an ongoing pattern of distribution by Atlas Venture funds, which have sold over $18.9 million in Dyne Therapeutics shares in the past three months, contributing to a broader insider selling trend totaling over $51 million. This continued selling by a major investor could signal a reduction in conviction.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYN was trading at $20.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYN - Latest Insights

DYN
Nov 05, 2026, 7:25 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.63
Real-time Price: $15.98 info
Change: -$2.65 (-14%) info
Market Cap: $3.004B info
DYN
Sep 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.78
Real-time Price: $15.98 info
Change: +$0.200 (+1%) info
Market Cap: $3.004B info
DYN
Sep 29, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $15.98 info
Change: +$0.200 (+1%) info
Market Cap: $3.004B info
DYN
Aug 17, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $26.15
Real-time Price: $15.98 info
Change: -$10.17 (-39%) info
Market Cap: $3.004B info
DYN
Aug 14, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.94
Real-time Price: $15.98 info
Change: -$9.96 (-38%) info
Market Cap: $3.004B info